Trial Profile
A Long-Term Efficacy and Safety Study of Infliximab in the Treatment of Moderate to Severe Plaque-Type Psoriasis [EXTENSION OF 700049383]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms RESTORE2
- Sponsors Merck & Co
- 04 Nov 2019 Trial has been completed in Germany.
- 13 Jun 2019 Trial has been discontinued in UK and Spain.
- 09 Jun 2019 Trial has been completed in Netherland.